Helping you find insights on psychedelics as medicine

Papers | Companies | Reports | Events

Leverage our research to stay up-to-date with the
psychedelic transition from trials to practice

Congressional Leaders Urge Psychedelics Research For PTSD And Depression In Updated Spending Measures
Congressional interest in psychedelics continues as a manager’s amendment to legislation covering the Department of Health and Human Services contains two sections addressing the therapeutic potential of psychedelics.
Published: 2022-07-05
Federal Health Officials Say Psychedelics’ Illegal Status Makes It Harder For Researchers To Study Them
Officials at two agencies within the National Institutes of Health (NIH) have acknowledged in a letter to two U.S. senators that federal prohibition makes it harder to study the benefits of psychedelics, requiring researchers to jump through additional regulatory hoops.
Published: 2022-07-05
It’s time to build psychedelic infrastructure
Health systems are unprepared to offer and meet the demand for psychedelic-assisted therapy - we can start to prepare now.
Category: Blossom's Bits
Published: 2022-07-05
Is funding for psychedelic research changing?
The legal issues and stigma surrounding psychedelics have deterred many traditional sources from funding - now, things are changing.
Category: Blossom's Bits
Published: 2022-07-05
The next generation of psychedelics
The next generation of psychedelics is already here – let's take a look at the advantages and disadvantages.
Category: Blossom's Bits
Published: 2022-07-05
The Size of the Psychedelic Market
Despite psychedelics remaining highly controlled – it hasn’t deterred investors and a sizeable market has developed.
Category: Blossom's Bits
Published: 2022-07-05
Brain dynamics predictive of response to psilocybin for treatment-resistant depression
This preprint (2022) reanalysed fMRI data from a previous open-label study where psilocybin was used in the treatment of treatment-resistant depression (TRD). After using whole-brain models to fit the spatiotemporal brain dynamics, dynamic sensitivity analysis identified brain regions in transition from a depressive brain state to a healthy one. The identified regions correlate with in vivo density maps of serotonin receptors 5-HT2A and 5-HT1A, providing further evidence for the role of serotonergic signalling in the recovery of depression via psilocybin.
Category: Papers
Published: 2022-07-05
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
This preprint (2022) reanalyses the data of a clinical trial in which the effects of psilocybin were compared to that of the SSRI escitalopram for major depressive disorder. Bayesian reanalysis found indeterminate evidence that psilocybin is superior that escitalopram using the QIDS SR-16 while strong evidence favoured psilocybin when using the BDI-1D and MADRS and extremely strong evidence when using the HAMD-17. The results support the idea that psilocybin outperformed escitalopram but was not clinically meaningful and, psilocybin is almost certainly non-inferior to escitalopram.
Category: Papers
Published: 2022-07-05
Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression
This posthoc analysis explored the effects of six repeated ketamine infusions (0.5mg/kg) in participants with anxious depression (n = 92) and nonanxious depression (n = 43). Anxious depressed patients were associated with a relatively lower antianhedonic response (47.8 % versus 51.2 %, p > 0.05) and remission (17.4 % versus 27.9 %, p > 0.05) than their non-anxious counterparts. Across both groups, a significant reduction in anhedonic symptoms was observed from the first infusion to the last infusion and at a 2-week follow-up.
Category: Papers
Published: 2022-07-05
Psychedelic Research Recap June 2022
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we're continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.
Category: Overviews
Published: 2022-07-05

Join us this September at ICPR Psychedelic Science, Ethics & Business

Experience a full conference day dedicated to the intersection of science and business in psychedelics.

Get Tickets

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Find the right paper, company, person in over 3.000 entries & 100.000 parameters

Explore Databases

Well-Researched Reports

Survey the psychedelic landscape with reports on 18 topics, 14 compounds & 20 countries

Explore Reports

Timely Insights

Stay in the loop with the latest articles on research & implementation

Explore Insights

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

A weekly email, sent on Tuesdays, packed with the latest
psychedelic research, news & actionable insights

Work with Blossom

Collaborate on a Report

Put your brand in the spotlight by helping us explore a research area

Collaborate

Associate your brand with our research & get highlighted in the newsletter & search results

Sponsor

Hire our team

Get expert support with writing & editing psychedelic resources

Hire us

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The Blossom newsletter is a terrific service to the psychedelic research community: a weekly digest that summarises major new findings in a clear, efficient, and informative way. It is a godsend for busy researchers trying to keep abreast of new developments in an increasingly fast-moving field.”

Chris Letheby

Lecturer in Philosophy, University of Western Australia
Author, Philosophy of Psychedelics

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Blossom newsletter and database are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report